N-Acetyl-L-Phenylalanine

We are N-Acetyl-L-Phenylalanine CAS:2018-61-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


N-Acetyl-L-Phenylalanine
CAS:2018-61-3
 

Solubility in methanol Colorless & almost clear (c=5)
Specific rotation [α]D25 +38.0°~+41.0°(c= 5, methanol)
Loss on drying Not more than 0.5%
Residue on ignition (as sulfate) Not more than 0.2%
Chloride (Cl) Not more than 0.05%
Sulfate (SO4) Not more than 0.02%
Heavy metals (as Pb) Not more than 15ppm
Arsenic (As2O3) Not more than 1ppm
Assay Not less than 98.5%

 

N-Acetyl-L-Phenylalanine


Related News: The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market.1-Bromo-3,3-Dimethyl-Butane In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.4-Methoxyphenylacetonitrile CAS:104-47-2 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.149490-60-8 As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.

Related Products
Product Name
N,N-diphenylimidazole-1-carboxamide View Details
5-Methylpyridine-2,3-dicarboxylic acid View Details
5-Bromo-2,3-dichloropyridine View Details
1-bromo-2-iodoethane manufacturer ethyl 3-(nitromethyl)hexanoate manufacturer 4-aminobenzenesulfonic acid manufacturer 4-Amino-6-methoxypyrimidine manufacturer 2-(7-methoxynaphthalen-1-yl)ethanamine,hydrochloride manufacturer